XML 58 R48.htm IDEA: XBRL DOCUMENT v3.25.3
SEGMENT REPORTING - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2025
Sep. 30, 2024
Segment Reporting Information [Line Items]                
Total segment revenue $ 14,262     $ 388     $ 243,676 $ 508
Research and development (19,519)     (49,225)     (111,731) (127,998)
Stock-based compensation (3,986)     (8,817)     (21,391) (25,672)
Depreciation expense             (1,109) (897)
Income tax (provision) benefit 1,424     0     (6,397) 0
Net income (loss) (7,280) $ (30,696) $ 148,451 (52,956) $ (45,257) $ (43,114) 110,475 (141,327)
Reportable Segment                
Segment Reporting Information [Line Items]                
Total segment revenue 14,262     388     243,676 508
Compensation costs (excluding stock based compensation) (9,568)     (11,830)     (37,187) (35,186)
Stock-based compensation (3,986)     (8,817)     (21,391) (25,672)
Depreciation expense (395)     (315)     (1,109) (897)
Other segment items (8,346)     (6,840)     (29,187) (20,529)
Dividend income 6,933     5,793     20,845 16,977
Income tax (provision) benefit 1,424     0     (6,397) 0
Net income (loss) (7,280)     (52,956)     110,475 (141,327)
KER-065 program expenses | Reportable Segment                
Segment Reporting Information [Line Items]                
Research and development (1,345)     (4,935)     (4,293) (12,225)
Elritercept program expenses | Reportable Segment                
Segment Reporting Information [Line Items]                
Research and development (3,341)     (13,576)     (37,872) (33,161)
Cibotercept program expenses | Reportable Segment                
Segment Reporting Information [Line Items]                
Research and development (1,218)     (8,618)     (11,185) (20,820)
Preclinical & development expenses | Reportable Segment                
Segment Reporting Information [Line Items]                
Research and development $ (1,700)     $ (4,206)     $ (5,425) $ (10,322)